Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

By Natalie Morrison

- Last updated on GMT

Related tags: European union, Vp, Executive director

The proposed changes to European clinical trial regulations accepted by the European Commission (EC) in July will put Europe on an equal playing field, according to Clinipace’s Andrea Schiefer.

Speaking to Outsourcing-Pharma.com, the firm's VP of European clinical operations and executive director of pharmacovigilance said the directive will correct the mistakes of the past that have caused a reduction of clinical trials in Europe.

When asked if it is ethical to make one market very attractive for conducting trials, she said: “I don’t think it will lead to a great influx in trials. It will be a slow development and it will make it more proportionate and more fair compared to the situation now.”

Schiefer added that if anything, the EC could have implemented more scientific expert committees looking at certain indications when forming the new guidelines.

Related news

Show more

Related products

show more

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars